Werner H. Poewe

Q: What Schools Are Affiliated With Werner H. Poewe

Werner H. Poewe is affiliated with the following schools: University of Innsbruck, Medical University of Innsbruck, University of Verona, University of Vienna

Werner H. Poewe's AcademicInfluence.com Rankings

Werner H. Poewe

Medical

#899

World Rank

#1160

Historical Rank

Neurology

#75

World Rank

#122

Historical Rank

medical Degrees

Download Badge

Medical

Werner H. Poewe's Degrees

Doctorate Medicine Medical University of Innsbruck

Why Is Werner H. Poewe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Werner H. Poewe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
MDS clinical diagnostic criteria for Parkinson's disease (2015) (3560)
Second consensus statement on the diagnosis of multiple system atrophy (2008) (2532)
A randomized trial of deep-brain stimulation for Parkinson's disease. (2006) (2460)
Clinical diagnostic criteria for dementia associated with Parkinson's disease (2007) (2413)
Parkinson disease (2017) (1821)
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease (2004) (1771)
The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria (2017) (1150)
Rivastigmine for dementia associated with Parkinson's disease. (2004) (1113)
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease (2011) (1005)
Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (2007) (918)
MDS research criteria for prodromal Parkinson's disease (2015) (897)
Pallidal deep-brain stimulation in primary generalized or segmental dystonia. (2006) (880)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study (2003) (828)
Early consolidation in human primary motor cortex (2002) (780)
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. (2011) (778)
Depression rating scales in Parkinson's disease: Critique and recommendations (2007) (616)
Prevalence and incidence of Parkinson's disease in Europe (2005) (608)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial (2005) (563)
Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease (2004) (534)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. (2009) (526)
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy (2017) (502)
Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia (2013) (502)
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease (2011) (493)
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) (2004) (443)
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2010) (443)
The Onset of Nonmotor Symptoms in Parkinson's disease (The ONSET PD Study) (2015) (405)
Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. (1997) (401)
Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER) (2010) (398)
Chronic Infections and the Risk of Carotid Atherosclerosis: Prospective Results From a Large Population Study (2001) (395)
Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease (2014) (384)
The natural history of multiple system atrophy: a prospective European cohort study (2013) (376)
Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology (2006) (374)
Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 (2005) (371)
Levodopa in the treatment of Parkinson's disease: Current controversies (2004) (370)
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study (2010) (360)
Non‐motor symptoms in Parkinson’s disease (2008) (359)
EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease (2013) (355)
Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study) (1996) (352)
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial (2007) (349)
Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. (2001) (347)
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study (2010) (337)
Validation of the freezing of gait questionnaire in patients with Parkinson's disease (2009) (332)
Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease (2013) (305)
A prevalence study of primary dystonia in eight European countries (2000) (302)
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination (1998) (300)
Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. (2012) (299)
Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations (2008) (292)
Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease (2013) (287)
Treatment interventions for Parkinson's disease: an evidence based assessment (2002) (280)
Deep brain stimulation: Preoperative issues (2006) (278)
Multiple system atrophy: A primary oligodendrogliopathy (2008) (274)
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome (2008) (269)
Restless legs syndrome (2005) (266)
SNCA variants are associated with increased risk for multiple system atrophy (2009) (263)
Prevalence of movement disorders in men and women aged 50–89 years (Bruneck Study cohort): a population-based study (2005) (257)
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong (2010) (256)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease (2006) (256)
Influence of Concurrent Tasks on Gait: A Dual-Task Approach (1995) (254)
Minimal clinically important change on the unified Parkinson's disease rating scale (2006) (250)
Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa (2007) (249)
Seminar on choreas (2006) (246)
Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations (2011) (245)
Anxiety rating scales in Parkinson's disease: Critique and recommendations (2008) (242)
Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. (2002) (240)
Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study (2000) (239)
Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy (2003) (237)
The natural history of parkinson's disease (1998) (237)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
Neurological Outcome of Septic Cardioembolic Stroke After Infective Endocarditis (2006) (226)
Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations (2010) (225)
Comparative analysis of gait in Parkinson's disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy. (1999) (224)
Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. (2011) (220)
Multiple system atrophy (2004) (218)
Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease (2000) (214)
Recanalization after thrombolysis in stroke patients (2007) (214)
Chronic Infections and the Risk of Carotid Atherosclerosis Prospective Results From a Large Population Study (2001) (214)
Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry (2010) (212)
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease (2007) (212)
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport® (1998) (208)
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study (2017) (208)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (2011) (207)
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial (2008) (204)
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease (2010) (203)
Microglial activation mediates neurodegeneration related to oligodendroglial α‐synucleinopathy: Implications for multiple system atrophy (2007) (202)
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) (2002) (199)
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial (2016) (199)
Red flags for multiple system atrophy (2008) (198)
Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome (2005) (193)
The diagnosis of Parkinson's disease (2006) (193)
Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group (2014) (193)
Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. (2005) (191)
Therapies in Parkinson's disease. (2012) (190)
Toward a redefinition of Parkinson's disease (2012) (187)
White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion‐tensor imaging and voxel‐based morphometry study (2011) (186)
The impact of blepharospasm and cervical dystonia on health-related quality of life and depression (2002) (185)
The Concept of Prodromal Parkinson’s Disease (2015) (185)
Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease (2010) (183)
Parkinson disease and the immune system — associations, mechanisms and therapeutics (2020) (182)
Low‐dose L‐dopa therapy in Parkinson's disease (1986) (177)
Management of spasticity associated pain with botulinum toxin A. (2000) (176)
Milestones in Parkinson's disease therapeutics (2011) (175)
Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1 (2011) (172)
Parkinson's disease and sleep (2000) (168)
How to diagnose dementia with Lewy bodies: State of the art (2005) (166)
Voxel‐based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy (2003) (165)
Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD (2015) (164)
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease (2009) (163)
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain (2006) (162)
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial (2018) (161)
Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. (2011) (159)
A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics (2008) (158)
Progression of falls in postmortem‐confirmed Parkinsonian disorders (1999) (158)
Scales to assess psychosis in Parkinson's disease: Critique and recommendations (2008) (158)
Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis (2017) (156)
Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) (2010) (155)
Prevalence and Burden of Gait Disorders in Elderly Men and Women Aged 60–97 Years: A Population-Based Study (2013) (154)
Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. (2008) (154)
Treatments for Parkinson disease—past achievements and current clinical needs (2009) (154)
Dystonia in multiple system atrophy (2002) (153)
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia (2002) (153)
Validation of the MDS clinical diagnostic criteria for Parkinson's disease (2018) (153)
Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease (2004) (152)
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial (2013) (149)
The natural history of Parkinson’s disease (1996) (147)
Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease (2009) (147)
Dystonia in parkinson's disease: Clinical and pharmacological features (1988) (146)
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities (2013) (144)
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. (2015) (144)
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (143)
Challenges in the diagnosis of Parkinson's disease (2021) (140)
Brain perfusion scintigraphy with99mTc-HMPAO or99mTc-ECD and123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease (1997) (138)
Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: Results from a prospective, randomized sham‐controlled trial (2008) (138)
Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder (2017) (138)
Neuropathological criteria of anti-IgLON5-related tauopathy (2016) (135)
Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients (1997) (134)
Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. (2006) (134)
Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study (2011) (132)
AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study (2013) (130)
Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model (2010) (129)
Voxel based morphometry reveals specific gray matter changes in primary dystonia (2007) (129)
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (128)
The clinical progression of Parkinson's disease. (2009) (127)
Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7T MRI (2014) (127)
Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using 123I-β-CIT and 123I-IBZM (2000) (127)
Premotor signs and symptoms of multiple system atrophy (2012) (127)
Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. (1996) (126)
Kava and dopamine antagonism. (1995) (126)
The prevalence of primary dystonia in the general community (2002) (125)
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations. (2015) (124)
Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. (2005) (124)
Defining at‐risk populations for Parkinson's disease: Lessons from ongoing studies (2012) (124)
Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study (2006) (123)
A genome-wide association study in multiple system atrophy (2016) (122)
Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia. (2016) (121)
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. (2017) (121)
Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study (2000) (120)
Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. (2015) (120)
Apomorphine: An underutilized therapy for Parkinson's disease (2000) (120)
Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease (2013) (119)
Video analysis of motor events in REM sleep behavior disorder (2007) (119)
The PRIPS study: screening battery for subjects at risk for Parkinson's disease (2013) (118)
Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review (2013) (118)
Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument (2004) (117)
Midbrain sonography in patients with essential tremor (2007) (115)
Dorsolateral nigral hyperintensity on 3.0T susceptibility‐weighted imaging in neurodegenerative Parkinsonism (2015) (114)
Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) (2006) (112)
Progression of brain atrophy in multiple system atrophy (2007) (112)
Akathisia, restless legs and periodic limb movements in sleep in Parkinson’s disease (2004) (111)
Meta‐analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease (2017) (111)
Active and Passive Smoking, Chronic Infections, and the Risk of Carotid Atherosclerosis: Prospective Results From the Bruneck Study (2002) (111)
Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin (2007) (110)
Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. (1999) (109)
Allergic rhinitis, asthma, and atherosclerosis in the Bruneck and ARMY studies. (2005) (108)
Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor (1997) (105)
Mortality in Parkinson's disease: A 38‐year follow‐up study (2015) (104)
Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder (2015) (104)
Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor (2012) (103)
Health‐related quality of life in multiple system atrophy (2006) (101)
The auditory startle reaction in parkinsonian disorders (2001) (100)
Clinical and polymyographic investigation of spasmodic torticollis (2004) (100)
Low concentrations of STI571 in the cerebrospinal fluid: a case report (2002) (100)
The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. (2009) (100)
Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. (2017) (99)
Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations (2010) (99)
Role of DAT‐SPECT in the diagnostic work up of Parkinsonism (2007) (99)
Levodopa in the treatment of Parkinson’s disease (2009) (98)
Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. (2010) (97)
Diagnosis and management of Parkinson's disease dementia (2008) (97)
High‐speed memory scanning in Parkmson's disease: Adverse effects of levodopa (1991) (96)
Diffusion weighted imaging best discriminates PD from MSA‐P: A comparison with tilt table testing and heart MIBG scintigraphy (2007) (96)
Movement disorder society criteria for clinically established early Parkinson's disease (2018) (96)
Depression in Parkinson's disease: impediments to recognition and treatment options. (1999) (95)
Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study (2006) (94)
Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. (2010) (93)
Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease (2008) (93)
Wearing‐off scales in Parkinson's disease: Critique and recommendations (2011) (92)
Costs of illness and care in Parkinson's Disease: An evaluation in six countries (2011) (92)
Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder (2009) (91)
Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial (2008) (90)
Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (1999) (90)
Probabilistic mapping of the antidystonic effect of pallidal neurostimulation: a multicentre imaging study. (2019) (89)
Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease (2010) (89)
Atrophy pattern in SCA2 determined by voxel-based morphometry (2003) (89)
Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. (1995) (89)
Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). (2011) (88)
Replication of restless legs syndrome loci in three European populations (2009) (88)
Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. (2012) (87)
Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. (2015) (87)
Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model (2012) (87)
Delayed diagnosis, range of severity, and multiple sleep comorbidities: a clinical and polysomnographic analysis of 100 patients of the innsbruck narcolepsy cohort. (2013) (86)
Management of Motor and Non-Motor Symptoms in Parkinson’s Disease (2013) (85)
Clinical exome sequencing in early‐onset generalized dystonia and large‐scale resequencing follow‐up (2017) (85)
Usefulness of the SINBAR electromyographic montage to detect the motor and vocal manifestations occurring in REM sleep behavior disorder. (2011) (85)
Comparison of diffusion‐weighted imaging and [123I]IBZM‐SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease (2004) (84)
Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration (1999) (84)
Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. (2011) (84)
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (2022) (84)
Repetitive speech phenomena in Parkinson's disease (2000) (83)
Glial cell death induced by overexpression of α‐synuclein (2001) (83)
The differential diagnosis of Parkinson's disease. (2002) (83)
Probable RBD and association with neurodegenerative disease markers: A population‐based study (2015) (83)
Validation of the Innsbruck REM sleep behavior disorder inventory (2012) (81)
The need for neuroprotective therapies in Parkinson’s disease (2006) (80)
Extended-release pramipexole in early Parkinson disease (2011) (80)
Supine hypertension in Parkinson’s disease and multiple system atrophy (2016) (79)
Sex-related influences on the frequency and age of onset of primary dystonia (1999) (79)
Clinical characteristics of the geste antagoniste in cervical dystonia (2001) (79)
Riluzole in Huntington's disease (HD): an open label study with one year follow up (2001) (79)
Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study (2006) (78)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. (2006) (78)
Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism (2016) (78)
Clinical measures of progression in Parkinson's disease (2009) (78)
Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility‐weighted imaging in idiopathic rapid eye movement sleep behavior disorder (2016) (78)
Increased daytime sleepiness in Parkinson's disease: A questionnaire survey (2003) (77)
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial (2015) (76)
Which dyskinesia scale best detects treatment response? (2013) (75)
Voxel-based morphometry in narcolepsy. (2005) (75)
Novel formulations and modes of delivery of levodopa (2015) (75)
Efficacy and safety of a standardised 500 unit dose of Dysport® (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study (2001) (75)
Motoric cognitive risk syndrome: Multicenter incidence study (2015) (75)
Premorbid personality of Parkinson patients. (1983) (75)
Genetics of restless legs syndrome (RLS): State‐of‐the‐art and future directions (2007) (74)
The new definition and diagnostic criteria of Parkinson's disease (2016) (74)
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy (2008) (74)
Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease (2002) (74)
Prevalence of Primary Headaches and Cranial Neuralgias in Men and Women Aged 55–94 Years (Bruneck Study) (2009) (73)
Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study (2006) (73)
Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation (2010) (73)
Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. (1993) (73)
Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease (2012) (73)
Trick maneuvers in cervical dystonia: Investigation of movement‐ and touch‐related changes in polymyographic activity (1999) (72)
Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community (2016) (72)
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features (2018) (71)
Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy (2012) (71)
Long-Term Follow-up Investigation of Isolated Rapid Eye Movement Sleep Without Atonia Without Rapid Eye Movement Sleep Behavior Disorder: A Pilot Study. (2015) (71)
How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy (2019) (71)
A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type (2013) (71)
Genome-wide association study in essential tremor identifies three new loci (2016) (70)
SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE (1988) (69)
Five‐year follow‐up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder (2014) (69)
Cortical atrophy in the cerebellar variant of multiple system atrophy: A voxel‐based morphometry study (2006) (68)
Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study (2010) (68)
Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain‐to‐pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy (2010) (68)
Targeted overexpression of human α-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure (2010) (68)
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine (2018) (68)
REM sleep behavior disorder in 703 sleep-disorder patients: the importance of eliciting a comprehensive sleep history. (2010) (68)
Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release (2014) (68)
Teaching program for the movement disorder society‐sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS‐UPDRS) (2010) (67)
Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease (2001) (67)
Psychosis in Parkinson's disease (2003) (67)
Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges (1999) (67)
Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. (1986) (67)
Perspectives on recent advances in the understanding and treatment of Parkinson’s disease (2009) (67)
Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. (2017) (67)
Mortality in Parkinson's disease: A 20‐year follow‐up study (2009) (66)
Treatment of dementia with Lewy bodies and Parkinson's disease dementia (2005) (66)
Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. (2006) (64)
Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome (2003) (64)
Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study (2014) (64)
Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. (1999) (63)
Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. (2005) (63)
Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease. (1996) (63)
Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. (1998) (63)
Interference of rhythmic constraint on gait in healthy subjects and patients with early parkinson's disease: Evidence for impaired locomotor pattern generation in early Parkinson's disease (1999) (63)
Differences in MDS‐UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration (2016) (63)
Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia (2002) (63)
Characterization of patients with longstanding idiopathic REM sleep behavior disorder (2017) (63)
Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations (2019) (62)
Periodic leg movements during sleep and periodic limb movement disorder in patients presenting with unexplained insomnia (2009) (62)
Treatment options for depression and psychosis in Parkinson's disease (2001) (62)
Social and clinical determinants of quality of life in Parkinson’s disease in Austria: a cohort study (2010) (62)
Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. (2021) (60)
The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. (1990) (60)
Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care (2013) (60)
Restless legs syndrome in Parkinson's disease (2009) (60)
Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson’s Disease: A Cross-Sectional Study (2018) (59)
Cerebral vasoreactivity decreases overnight in severe obstructive sleep apnea syndrome: a study of cerebral hemodynamics. (2009) (59)
A critique of the second consensus criteria for multiple system atrophy (2019) (59)
Disturbance of rapid eye movement sleep in spinocerebellar ataxia type 2 (2006) (58)
Ischemic stress induces deposition of amyloid β immunoreactivity in human brain (2004) (58)
Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study (2007) (58)
The natural course of Sneddon syndrome: clinical and magnetic resonance imaging findings in a prospective six year observation study (2003) (58)
Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice (2003) (58)
Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. (2013) (57)
123I‐β‐CIT and 123I‐IBZM‐SPECT scanning in levodopa‐naive Parkinson's disease (1998) (57)
Emerging therapies for Parkinson's disease. (2012) (57)
Trial designs used to study neuroprotective therapy in Parkinson's disease (2013) (57)
Dysautonomia and cognitive dysfunction in Parkinson's disease (2007) (56)
Transient and permanent magnetic resonance imaging abnormalities after complex partial status epilepticus (2006) (56)
The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension (2011) (56)
Progression of parkinsonism in multiple system atrophy (2005) (56)
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial (2020) (55)
The reorganization of functional architecture in the early-stages of Parkinson's disease. (2018) (55)
Investigation of autonomic function in idiopathic REM sleep behavior disorder (2012) (54)
Juvenile asymmetric segmental spinal muscular atrophy (Hirayama's disease) Three cases without evidence of “flexion myelopathy” (2001) (54)
Mortality in Parkinson's disease, a 20‐year follow‐up study (2009) (53)
Evaluation of Striatal Dopamine Transporter Function in Rats by in Vivo β-[123I]CIT Pinhole SPECT (2002) (52)
Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER (2012) (52)
Validation of an integrated software for the detection of rapid eye movement sleep behavior disorder. (2014) (52)
Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population‐based 10‐year study (2018) (51)
Mavoglurant in Parkinson's patients with l‐Dopa‐induced dyskinesias: Two randomized phase 2 studies (2016) (50)
Depression in Parkinson's disease. An update. (2001) (50)
Abnormalities of dopaminergic neurotransmission in SCA2: A combined 123I‐βCIT and 123I‐IBZM SPECT study (2004) (50)
Magnetic resonance imaging in the diagnosis of spinal cord diseases. (1985) (50)
Elastin Polymorphism Haplotype and Intracranial Aneurysms Are Not Associated in Central Europe (2003) (50)
Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly (2010) (50)
Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy) (2003) (49)
Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study (2017) (49)
IgLON5 autoimmunity and abnormal behaviours during sleep (2015) (49)
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits (2015) (48)
Quantification of sensory trick impact on tremor amplitude and frequency in 60 patients with head tremor (2000) (48)
PLM detection by actigraphy compared to polysomnography: a validation and comparison of two actigraphs. (2009) (48)
Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies (2004) (47)
Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature (2014) (47)
The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. (2018) (47)
Can observers link dream content to behaviours in rapid eye movement sleep behaviour disorder? A cross‐sectional experimental pilot study (2012) (47)
Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. (1999) (47)
Treatment of spasmodic torticollis with local injections of botulinum toxin (2004) (47)
Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone (2020) (47)
Freezing of gait in postmortem‐confirmed atypical parkinsonism (2002) (47)
Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. (2018) (47)
Transient restless legs syndrome after spinal anesthesia (2002) (46)
An Essay on Wilhelm von Humboldt and the Shaking Palsy (1995) (46)
Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson’s Disease Dementia (2008) (46)
Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies (2018) (46)
Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. (1994) (45)
Detecting nocturnal hypertension in Parkinson’s disease and multiple system atrophy: proposal of a decision-support algorithm (2014) (45)
Abolishing the 1‐year rule: How much evidence will be enough? (2016) (45)
Trial of Cinpanemab in Early Parkinson's Disease. (2022) (45)
Application of the International Cooperative Ataxia Scale rating in multiple system atrophy (2002) (44)
Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study (2015) (44)
Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease (2016) (44)
Brain structural profile of multiple system atrophy patients with cognitive impairment (2017) (44)
The Safety of Ropinirole, a Selective Nonergoline Dopamine Agonist, in Patients with Parkinson's Disease (1998) (43)
Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia types 2 and 6 (2001) (43)
Diffusion‐weighted imaging in Huntington's disease (2006) (43)
Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease (2010) (43)
The relation between abnormal behaviors and REM sleep microstructure in patients with REM sleep behavior disorder. (2009) (42)
Hemimasticatory spasm in hemifacial atrophy: Diagnostic and therapeutic aspects in two patients (1995) (42)
Levodopa: 50 years of a revolutionary drug for Parkinson disease (2015) (42)
Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study (2010) (42)
Trial of Prasinezumab in Early-Stage Parkinson's Disease. (2022) (41)
Safety of prolonged sacral neuromodulation tined lead testing* (2008) (41)
Risk factors and prodromal markers and the development of Parkinson’s disease (2013) (41)
Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients (1998) (41)
Late (Complicated) Parkinson's Disease (2010) (40)
White and gray matter abnormalities in narcolepsy with cataplexy. (2012) (40)
The rigid spine syndrome--a myopathy of uncertain nosological position. (1985) (40)
Toward a primate model of l‐dopa‐unresponsive parkinsonism mimicking striatonigral degeneration (2000) (40)
Alpha-synuclein immunoreactivity patterns in the enteric nervous system (2015) (40)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease (2006) (40)
Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis (2017) (40)
New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study (2015) (40)
Klüver-Bucy syndrome in man: Experiences with posttraumatic cases (1983) (40)
The clinical spectrum of levodopa-induced motor complications (2010) (39)
The role of COMT inhibition in the treatment of Parkinson’s disease (2004) (39)
MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. (2018) (39)
Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions (2019) (39)
Amyloid β‐peptide and the dementia of Parkinson's diease (1996) (39)
A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy (2020) (39)
Decision making and executive functions in REM sleep behavior disorder. (2012) (38)
Fragmentary myoclonus in sleep revisited: a polysomnographic study in 62 patients. (2011) (38)
Parkinson's disease and arithmetics: The role of executive functions (2006) (37)
Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch (2010) (37)
Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT (2012) (37)
VPS35 Parkinson’s disease phenotype resembles the sporadic disease (2014) (37)
Effects of Erythropoietin on Frataxin Levels and Mitochondrial Function in Friedreich Ataxia – a Dose–Response Trial (2011) (37)
Reply: Role of DAT SPECT in the diagnostic work‐up of Parkinsonism (2008) (36)
Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease (2016) (36)
Towards translational therapies for multiple system atrophy (2014) (36)
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease (2018) (36)
Nonmotor Symptoms in Subjects Without Evidence of Dopaminergic Deficits (2015) (36)
A Prospective Video-Polysomnographic Analysis of Movements during Physiological Sleep in 100 Healthy Sleepers. (2015) (35)
Towards Neurotransplantation in Multiple System Atrophy: Clinical Rationale, Pathophysiological Basis, and Preliminary Experimental Evidence (2000) (35)
Therapeutic strategies in multiple system atrophy (2005) (35)
Dystonis in ataxia telangiectasia: Report of a case with putaminal lesions and decreased striatal [123I]Iodobenzamide Binding (1994) (35)
Premotor Parkinson disease (2009) (34)
Seeing ophthalmologic problems in Parkinson disease (2020) (34)
APOMORPHINE TEST FOR DOPAMINERGIC RESPONSIVENESS (1989) (34)
Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study. (2004) (34)
Cervical dystonia in spinocerebellar ataxia type 2: clinical and polymyographic findings (2006) (34)
Restless legs syndrome and motor activity during sleep in spinocerebellar ataxia type 6. (2006) (34)
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. (2008) (34)
Tumor necrosis factor‐α‐induced cell death in U373 cells overexpressing α‐synuclein (2003) (34)
Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications (2015) (34)
Validation of a mail questionnaire for parkinsonism in two languages (German and Italian) (1999) (33)
Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia (2011) (33)
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients (2008) (33)
Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease (2010) (33)
Sensor‐based gait analysis in atypical parkinsonian disorders (2018) (33)
Should treatment of Parkinson's disease be started with a dopamine agonist? (1998) (32)
Clinical aspects of motor fluctuations in Parkinson's disease. (1994) (32)
Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized‐controlled trial (2016) (32)
Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study (2013) (32)
Early (Uncomplicated) Parkinson's Disease (2010) (31)
Deep brain stimulation in Huntington's disease: A 4‐year follow‐up case report (2012) (31)
Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial (2018) (31)
The ‘risus sardonicus’ of multiple system atrophy (2003) (31)
Family‐based association study of the restless legs syndrome loci 2 and 3 in a European population (2007) (31)
Computerized Tremor Analysis of Valproate‐induced Tremor: A Comparative Study of Controlled‐release versus Conventional Valproate (2005) (31)
New insights into atypical parkinsonism. (2011) (31)
The influence of deep brain stimulation on pain perception in Parkinson's disease (2011) (31)
The pharmacology of foot dystonia in parkinsonism. (1987) (31)
Distal myasthenia gravis – frequency and clinical course in a large prospective series (2003) (31)
Correlation of clinical response in apomorphine test with D2‐receptor status as demonstrated by 123I IBZM‐SPECT (1993) (31)
Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. (2015) (30)
Cerebrospinal fluid hypocretin‐1 levels in multiple system atrophy (2007) (30)
Molecular diversity of combined and complex dystonia: insights from diagnostic exome sequencing (2017) (30)
Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease: A Double-Blind, Randomized Trial (2012) (30)
Unilateral painful legs and moving toes syndrome with moving fingers—evidence for distinct oscillators (1998) (30)
The Sydney multicentre study of Parkinson’s disease (1999) (29)
Social stigmatization in patients with cranial and cervical dystonia (2006) (28)
Anticholinergic therapies in the treatment of Parkinson's disease (2002) (28)
Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy (2018) (28)
Auditory startle response in cervical dystonia (2003) (28)
Riluzole therapy in cervical dystonia (2002) (28)
Auditory startle reaction is disinhibited in idiopathic restless legs syndrome. (2007) (28)
Speech therapy in Parkinson's disease (2002) (28)
Predictors for mild parkinsonian signs: a prospective population-based study. (2015) (28)
Is Transcranial Sonography Useful to Distinguish Scans Without Evidence of Dopaminergic Deficit Patients From Parkinson's Disease? (2012) (28)
Amantadine in the treatment of Parkinson's disease and other movement disorders (2021) (27)
A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders (2011) (27)
The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach (2016) (27)
Sociocultural differences in gait (2000) (27)
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data (2021) (27)
Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats (2005) (27)
An open trial of levetiracetam for segmental and generalized dystonia (2007) (27)
Motor disturbances during non‐REM and REM sleep in narcolepsy–cataplexy: a video‐polysomnographic analysis (2011) (27)
Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis (1999) (27)
Erythropoietin in Friedreich ataxia (2013) (27)
Gray matter abnormalities of the dorsal posterior cingulate in sleep walking. (2017) (26)
Perseverative motor behaviour in Parkinson's disease (1994) (26)
Clinical trials in restless legs syndrome—Recommendations of the European RLS Study Group (EURLSSG) (2007) (26)
Natural course of restless legs syndrome/Willis-Ekbom disease: long-term observation of a large clinical cohort. (2015) (26)
Quantitative assessment of isolated rapid eye movement (REM) sleep without atonia without clinical REM sleep behavior disorder: clinical and research implications. (2014) (26)
P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study (2009) (26)
Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. (2006) (25)
A descriptive analysis of neck myoclonus during routine polysomnography. (2010) (25)
A prospective questionnaire study in 100 healthy sleepers: non-bothersome forms of recognizable sleep disorders are still present. (2014) (25)
The neuropsychiatric phenotype in CACNA1A mutations: a retrospective single center study and review of the literature (2018) (25)
Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. (2003) (25)
Mode of vagus nerve stimulation differentially affects sleep related breathing in patients with epilepsy (2009) (25)
Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease. (2020) (25)
Clinical studies with transdermal rotigotine in early Parkinson’s disease (2005) (25)
Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062) (2013) (25)
Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease (2014) (25)
Daytime sleepiness is not increased in mild to moderate multiple sclerosis: a pupillographic study. (2005) (25)
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety (2019) (25)
Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications (2016) (24)
The scale for the assessment and rating of ataxia correlates with dysarthria assessment in Friedreich's ataxia (2012) (24)
Therapeutics of Parkinson's disease and other movement disorders (2008) (24)
Multimodal Magnetic Resonance Imaging reveals alterations of sensorimotor circuits in restless legs syndrome. (2019) (24)
Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease (2013) (24)
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy (2018) (24)
Skeletal Muscle Involvement in Friedreich Ataxia and Potential Effects of Recombinant Human Erythropoietin Administration on Muscle Regeneration and Neovascularization (2012) (24)
Dose standardization of botulinum toxin. (1998) (23)
Adjuncts to levodopa therapy (1998) (23)
Experience with selegiline in the treatment of Parkinson's disease. (1987) (23)
Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis (2019) (23)
Asian perspectives on the recognition and management of levodopa ‘wearing-off’ in Parkinson’s disease (2015) (23)
Levodopa‐induced sleepiness in the Parkinson variant of multiple system atrophy (2006) (23)
Augmentation and impulsive behaviors in restless legs syndrome (2016) (22)
Safety Profile of Opicapone in the Management of Parkinson's Disease. (2019) (22)
Effects of rasagiline on the progression of nonmotor scores of the MDS‐UPDRS (2015) (22)
Striatal transplantation in a rodent model of multiple system atrophy: Effects on L‐Dopa response (2009) (22)
Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson's syndrome. (1994) (22)
Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: One year follow up results of a prospective multicenter trial. (2015) (22)
Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies (2014) (22)
Ninhydrin sweat test: A simple method for detecting antibodies neutralizing botulinum toxin type A (2004) (22)
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting (2018) (22)
Early distinction of Parkinson‐variant multiple system atrophy from Parkinson's disease (2019) (21)
Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study (2020) (21)
Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology. (1987) (21)
Cortical evoked potentials of the vesicourethral junction – a predictor for the outcome of intravesical electrostimulation in patients with sensory and motor detrusor dysfunction (1998) (21)
Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. (2019) (21)
The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. (2019) (21)
Intact Olfaction in a Mouse Model of Multiple System Atrophy (2013) (21)
Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. (2018) (20)
Bioenergetics of the Calf Muscle in Friedreich Ataxia Patients Measured by 31P-MRS Before and After Treatment with Recombinant Human Erythropoietin (2013) (20)
A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease (2010) (20)
Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease? (2016) (20)
Deprenyl (selegiline) in combination treatment of Parkinson's disease (1983) (20)
Facial recognition in primary focal dystonia (2006) (20)
Pharmacological study in Meige's syndrome with predominant blepharospasm. (1988) (20)
Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's. (2016) (20)
Cognition in multiple system atrophy: a single‐center cohort study (2020) (20)
Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study (2012) (20)
Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. (2019) (20)
Cerebral ergotism under treatment with ergotamine and ritonavir (2001) (20)
Auditory startle reaction in primary blepharospasm (2007) (19)
The role of insulin in age-related sex differences of cardiovascular risk profile and morbidity. (1997) (19)
Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration (2004) (19)
Amantadine and other antiglutamate agents (2002) (19)
Drug safety evaluation of rotigotine (2012) (19)
A follow‐up study of substantia nigra echogenicity in healthy adults (2012) (19)
Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease (2020) (19)
Pramipexole extended release in Parkinson’s disease (2011) (19)
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off (2015) (19)
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease (2014) (18)
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. (2021) (18)
Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): Placebo‐controlled, polysomnographic case report (2001) (18)
Subjective Visual Vertical in PD Patients with Lateral Trunk Flexion (2016) (18)
Therapeutic advances in multiple system atrophy and progressive supranuclear palsy (2015) (18)
Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. (2019) (18)
In vitro models of multiple system atrophy (2005) (18)
Consistency of “Probable RBD” Diagnosis with the RBD Screening Questionnaire: A Follow‐up Study (2017) (18)
Visuoperception and visuospatial and visuorotational performance in Parkinson's disease (1987) (18)
Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel (2018) (17)
Taking sides: Is handedness involved in motor asymmetry of Parkinson's disease? (2012) (17)
Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry (2018) (17)
Advances in Research on Neurodegeneration (2003) (17)
[Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease]. (1993) (17)
Is transcranial sonography useful to distinguish drug‐induced parkinsonism from Parkinson's disease? (2012) (17)
Spasmodic torticollis - a multicentre study on behavioural aspects IV: psychopathology. (1996) (17)
123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. (1998) (17)
Depression in Parkinson's disease (2007) (17)
Treatment of depression in idiopathic Parkinson's disease (2002) (17)
New hopes for disease modification in Parkinson's Disease (2020) (17)
SIDE-EFFECTS OF SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE (1989) (17)
Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor (2016) (16)
Animal models of multiple system atrophy (2005) (16)
Low Bone Mineral Density in Friedreich Ataxia (2014) (16)
Cortical and brain stem hyperexcitability in a pathologically confirmed case of multiple system atrophy (2000) (16)
Iodine-123-iodo-lisuride SPECT in Parkinson's disease. (1996) (16)
Cortical and brain stem hyperexcitability in striatonigral degeneration (1998) (16)
Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study) (2019) (16)
Prognostic Value of Intraventricular Blood in Perimesencephalic Nonaneurysmal Subarachnoid Hemorrhage (2001) (16)
Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy (2016) (16)
Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder (2020) (16)
Restless legs syndrome in Friedreich ataxia: A polysomnographic study (2011) (16)
Slowing of high-speed memory scanning in Parkinson's disease is related to the severity of parkinsonian motor symptoms (1990) (16)
Functional connectivity and topology in patients with restless legs syndrome: a case–control resting‐state functional magnetic resonance imaging study (2020) (15)
Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. (2019) (15)
Adenosine A2A receptor antagonists in Parkinson's disease: still in the running (2014) (15)
Urinary retention discriminates multiple system atrophy from Parkinson's disease (2019) (15)
Gait analysis to assess the effects of botulinum toxin type A treatment in cerebral palsy: an open‐label study in 10 children with equinus gait pattern (1999) (15)
Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD) (2015) (15)
Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. (2018) (15)
Involvement of Peripheral Nerves in the Transgenic PLP-α-Syn Model of Multiple System Atrophy: Extending the Phenotype (2015) (15)
Disturbances of dynamic balance in phasic cervical dystonia (1999) (15)
Restless legs syndrome (2005) (15)
IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. (2017) (15)
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study (2021) (15)
Deep brain stimulation reduces (nocturnal) dyskinetic exacerbations in patients with ADCY5 mutation: a case series (2020) (15)
Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement (2021) (15)
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study (2021) (15)
Autonomic function testing in Friedreich’s ataxia (2018) (15)
Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. (2019) (15)
Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy (2011) (15)
Efficacy of Rotigotine at Different Stages of Parkinson’s Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage (2016) (15)
Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. (2018) (15)
Prognostic implications of the motor symptoms of Parkinson's disease with respect to clinical, computertomographic and psychometric parameters (2005) (14)
Dystonia--a clinical, neuropathological and therapeutic review. (1992) (14)
Drugs to treat dementia and psychosis (2002) (14)
Identification of Restless Legs Syndrome Genes by Mutational Load Analysis (2019) (14)
No effects on heart‐rate variability and cardiovascular reflex tests after botulinum toxin treatment of cervical dystonia (1996) (14)
Atypische Parkinson-Syndrome (1997) (14)
Progressive multifocal leukoencephalopathy presenting with an isolated focal movement disorder (2000) (14)
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. (2018) (14)
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease (2012) (14)
The Unified Multiple System Atrophy Rating Scale: Intrarater reliability (2012) (14)
Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. (2020) (14)
Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations (2018) (14)
[Cost of illness and health service patterns in Morbus Parkinson in Austria]. (2009) (14)
MAO‐B inhibitors for the treatment of Parkinson's disease (2002) (13)
Automated Analysis of Diffusion‐Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease (2020) (13)
REM Sleep Behavior Disorder and REM Sleep Without Atonia are More Frequent in Advanced versus Early Parkinson's Disease. (2021) (13)
Periodic limb movement counting in polysomnography: effects of amplitude. (2006) (13)
Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2 p 14 and 16 q 12 . 1 (2017) (13)
Clinical Experiences with Budipine in Parkinson Therapy (1985) (13)
Magnetic resonance imaging and angiography in hemifacial spasm (2004) (13)
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study (2021) (12)
Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. (2020) (12)
Lack of Asymmetry of Nigrostriatal Dopaminergic Function in Healthy Subjects (2020) (12)
Success rate, efficacy, and safety/tolerability of overnight switching from immediate‐ to extended‐release pramipexole in advanced Parkinson's disease (2013) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy (2007) (12)
Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation (2017) (12)
Nonmotor symptoms in Parkinson’s disease (2013) (12)
Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa (2020) (12)
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [11C]PBR28 and Machine Learning Analysis (2021) (12)
Clinical and pathophysiologic aspects of late levodopa failure (1993) (11)
Autonomic function testing in spinocerebellar ataxia type 2 (2018) (11)
Akathisia induced by necrosis of the basal ganglia after carbon monoxide intoxication (1995) (11)
Movement disorders in systemic diseases. (2015) (11)
Psychometric findings in clinical subtypes of Parkinson's disease. (1987) (11)
Is there a polysomnographic signature of augmentation in restless legs syndrome? (2014) (11)
Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA (2017) (11)
[Dysequilibrium in idiopathic Parkinson disease. The effect of cerebrovascular comorbidity]. (2002) (11)
IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls. (1993) (11)
Parkinson disease: Treatment of the nonmotor symptoms of Parkinson disease (2010) (11)
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients (1992) (10)
Trial of Deferiprone in Parkinson's Disease. (2022) (10)
Impact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's Disease (2015) (10)
Long duration response in Parkinson's disease: levodopa revisited. (2020) (10)
The premorbid personality of patients with Parkinson's disease An early sign of their disease? (1989) (10)
A new tremor mutant in the pietrain pig: An animal model of orthostatic tremor? Clinical and neurophysiological observations (1997) (10)
On‐Demand Therapy for OFF Episodes in Parkinson's Disease (2021) (10)
Optimal deep brain stimulation sites and networks for cervical vs. generalized dystonia (2022) (10)
Is there a need to redefine Parkinson’s disease? (2013) (10)
Postoperative parkinsonian tremor in a patient with a frontal meningioma (1999) (10)
[Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group]. (1999) (10)
Minimally clinically important decline in the parkinsonian variant of multiple system atrophy (2016) (10)
Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
An early report of striatonigral degeneration (2000) (9)
Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy (2007) (9)
Correction: Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1 (2011) (9)
Parkinson's disease and the quest for preclinical diagnosis: an interview with Professor Werner Poewe. (2017) (9)
[Psychosomatic aspects of idiopathic spasmodic torticollis. Results of a multicenter study]. (1998) (9)
Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations. (1987) (9)
Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease (1999) (9)
Spasmodic torticollis - a multicentre study on behavioural aspects II: signs, symptoms and course. (1996) (9)
Oxcarbazepine in glossopharyngeal neuralgia: Clinical response and effect on serum lipids (2004) (9)
Spasmodic torticollis - a multicentre study on behavioural aspects III: psychosocial changes and coping. (1996) (9)
Pharmacogenetics of Parkinson's Disease in Clinical Practice (2017) (9)
Multiomics Analyses Identify Genes and Pathways Relevant to Essential Tremor (2020) (9)
Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy (2004) (9)
Parkinson disease: Intestinal levodopa infusion in PD—the first randomized trial (2014) (9)
Clinical features, diagnosis, and imaging of parkinsonian syndromes. (1993) (9)
[The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients]. (1992) (9)
Homocysteine and serum markers of immune activation in primary dystonia (2005) (9)
Towards seeing the visual impairments in Parkinson’s disease: protocol for a multicentre observational, cross-sectional study (2019) (8)
[Predictors of mental and physical quality of life in Huntington's disease]. (2015) (8)
3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes (1993) (8)
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease? (2022) (8)
Multiple system atrophy. (2004) (8)
Surgical treatment for Parkinson's disease: Deep brain surgery (2002) (8)
Memory dysfunction in Parkinson patients: an analysis of verbal learning processes. (1991) (8)
Large-scale TUBB4A mutational screening in isolated dystonia and controls. (2015) (8)
Reflection impulsivity perceptual decision‐making in patients with restless legs syndrome (2018) (8)
Copper genes are not implicated in the pathogenesis of focal dystonia. (2002) (8)
Current strategies in the drug treatment of advanced Parkinson's disease — new modes of dopamine substitution (1993) (8)
Differentialdiagnose der Parkinson-Erkrankungen - 123I-IBZM-SPECT vs. Apomorphin-Test (1993) (8)
CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease. (1990) (7)
Plasma fasting cholesterol profiles and age at onset in Parkinson's disease (2015) (7)
Can we define “pre‐motor” Parkinson's disease? (2012) (7)
Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson’s disease (2012) (7)
P2.152 Changes in early-morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system: two large, placebo-controlled trials (2009) (7)
Dynamic balance function in phasic cervical dystonia following Botulinum toxin therapy (2001) (7)
[The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test]. (1993) (7)
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II (2021) (7)
Chapter 2 – Drug Therapy: Dopamine Agonists (2005) (7)
Prodromal Parkinson's disease: hype or hope for disease-modification trials? (2022) (7)
How to run a "brain bank"? Clinical and institutional requirements for "brain banking". (1993) (7)
Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population‐Based 10‐Year Study (2021) (7)
High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence (2007) (7)
Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience (2020) (7)
Augmentation in restless legs syndrome: an eye tracking study on emotion processing (2020) (7)
Diagnostic potential of automated tractography in progressive supranuclear palsy variants. (2020) (7)
Dopaminergic-peptidergic interactions in extrapyramidal disorders: a review of the clinical evidence. (1987) (6)
1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism (2016) (6)
Is EEG useful in the differential diagnosis of parkinsonism? (1998) (6)
No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements (2020) (6)
Surgical treatment for Parkinson's disease: Neural transplantation (2002) (6)
Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population‐Based Cohort (2020) (6)
Characterization of gait variability in multiple system atrophy and Parkinson’s disease (2020) (6)
Use of botulinum toxin in the treatment of cervical dystonia. (1993) (6)
DA agonists ‐ Ergot derivaties: Cabergoline (2002) (6)
Has Deep Brain Stimulation Changed the Very Long‐Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study (2020) (6)
Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease. (1991) (6)
A Standardized MR Imaging Protocol for Parkinsonism (2020) (6)
Treatment of psychosis in Parkinson´s disease (2005) (6)
DA agonists ‐ Non‐Ergot derivaties: Ropinirole (2002) (6)
Addressing non-motor impairments in Parkinson's disease: The new version of the UPDRS (2005) (6)
Progression of Parkinson’s Disease and Unmet Needs in Mid- to Late-stage Patients (2015) (6)
Movement disorders: new insights into disease mechanisms and treatment (2014) (6)
Psychosocial counseling in Parkinson's disease (2002) (6)
Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy) (2005) (6)
Chapter 75 – Atypical Parkinsonism (2003) (6)
Phenotype variability in spinocerebellar ataxia type 2: A longitudinal family survey and a case featuring an unusual benign course of disease (2009) (5)
Global Scales to Stage Disability in PD: The Hoehn and Yahr Scale (2012) (5)
Separation from Mother at Time of Weaning (1986) (5)
Advances in Research on Neurodegeneration (1997) (5)
[Excessive daytime sleepiness: etiology, differential diagnosis and diagnostic procedures]. (2001) (5)
Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. (2021) (5)
Comparative analysis of gait in Parkinson's disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy (1999) (5)
Chronic idiopathic polyneuritis. (1983) (5)
Alpha-synuclein seeds in olfactory mucosa of patients with isolated rapid-eye-movement sleep behaviour disorder (2020) (5)
[Spinal fibrocartilaginous embolism]. (2005) (5)
Relevance of EARLYSTIM in a tertiary movement disorders center (2014) (5)
[Clinical subtypes of Parkinson disease]. (1986) (5)
Physical and occupational therapy in Parkinson's disease (2002) (5)
Reader response: Olfaction and incident Parkinson disease in US white and black older adults (2018) (5)
Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I]β-CIT SPECT analysis (2006) (5)
The Frontal Assessment Battery in RLS patients with and without augmentation. (2020) (4)
Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry (2020) (4)
Very late‐onset pure autonomic failure (2017) (4)
TOR1A, THAP1, and GNAL mutational screening in Austrian patients with primary isolated dystonia (2015) (4)
Axial myopathy in parkinsonism (2011) (4)
DA agonists ‐ Non‐Ergot derivaties: Apomorphine (2002) (4)
Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes (2016) (4)
Levodopa: back to the future (2010) (4)
High speed memory scanning in Parkinson's disease: Effects of L-Dopa (1989) (4)
Levodopa and Parkinson Disease-Myths Revisited. (2017) (4)
SOX5-Null Heterozygous Mutation in a Family with Adult-Onset Hyperkinesia and Behavioral Abnormalities (2017) (4)
[Therapeutic experiences with a slow-release preparation of L-dopa (Madopar "HBS") in patients with advanced Parkinson disease]. (1989) (4)
Undetected ophthalmological disorders in Parkinson’s disease (2022) (4)
[Brain SPECT with 123I-lisuride in patients with Parkinson's disease and controls]. (1995) (4)
Sleep and daytime sleepiness in Parkinson's disease (2003) (4)
Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using 123 I-β-CIT (2000) (4)
Rifampicin for multiple system atrophy (2014) (4)
Insulin signalling: new target for Parkinson's treatments? (2017) (4)
Sensitivity to Change and Patient‐Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data‐Driven Analysis (2022) (4)
Clinical Experience with Budipine in Parkinsonian Therapy (1985) (4)
Caveats of Neurodegenerative Risk Stratification in Idiopathic REM Sleep Behavior Disorder by Use of the MDS Research for Prodromal Parkinson's Disease. (2017) (4)
Substantia nigra hypoechogenicity in Friedreich ataxia (2012) (4)
Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport®) (2018) (4)
On “Polysomnography reveals unexpectedly high rates of organic sleep disorders in patients with prediagnosed primary insomnia” (Sleep Breath 2011 doi 10.1007/s11325-011-0608-8) (2013) (4)
Update on Treatments for Motor Symptom of Pd (4)
Intrafamilial heterogeneity of facial hyperkinesias: Chance association of tics, cranial dystonia, and Huntington's disease? (2001) (4)
Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy (2017) (4)
Diagnosis of drug‐induced parkinsonism: can transcranial sonography make the difference? (2013) (3)
CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. (1990) (3)
M6 Nabilone in huntington’s disease: a case series of five patients (2016) (3)
New version of the UPDRS: Development methods and working document for field testing (2005) (3)
A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson’s disease with dementia (2022) (3)
The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study (2021) (3)
Systematic TOR1A non-c.907_909delGAG variant analysis in isolated dystonia and controls. (2016) (3)
[Vascular parkinsonian syndrome]. (2006) (3)
Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006) (2018) (3)
Recent advances in the drug treatment of Parkinson's disease. (1999) (3)
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease (2022) (3)
Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008) (2018) (3)
Antiparkinsonian activity of a non‐ergot dopamine agonist, CV 205‐502, in patients with fluctuating Parkinson's disease (1990) (3)
A relapsing-remitting type of ocular myasthenia gravis without typical muscle fatiguability (2002) (3)
W01.41 Osteoprotegerin is a risk predictor of progressive atherosclerosis and cardiovascular disease (2004) (3)
Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson's disease patients recently diagnosed with motor fluctuations (2020) (3)
Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post‐hoc Analysis of NMS‐Nab Study (2022) (3)
Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) (2005) (3)
Influence of a Post-Test Factor on the Results of the Multiple Sleep Latency Test. (2016) (3)
SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases Add-On Therapy to Levodopa in Patients with Parkinson's disease (2010) (3)
Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eye‐Tracking Study (2021) (3)
The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis (2016) (3)
Primitive motor patterns and stereotyped movements. A comparison of findings in early childhood and in the apallic syndrome. (1982) (3)
Managing the Non‐Motor Symptoms of Parkinson's Disease (2008) (3)
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022? (2022) (3)
Decades of delayed diagnosis in 4 levodopa‐responsive young‐onset monogenetic parkinsonism patients (2011) (3)
Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study (2018) (3)
Atypical pineal teratoma: clinical and computer tomographic features of two patients with disseminated ependymal lesions. (1984) (3)
Reply: Nonmotor symptoms in subjects without evidence of dopaminergic deficits (2015) (3)
DA agonists ‐ Ergot derivaties: Lisuride (2002) (3)
adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study (2000) (3)
[MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation]. (2013) (2)
Impact of coexistent Alzheimer pathology on the natural history of dementia with Lewy bodies (2000) (2)
[Therapy of essential tremor with special reference to the use of beta-blockers]. (1982) (2)
[Clinical variants of pseudotumor cerebri syndrome]. (1995) (2)
The role of exposure to pesticides in the etiology of Parkinson’s disease: a 18F-DOPA positron emission tomography study (2018) (2)
New perspectives in non-oral drug delivery in Parkinson's disease: Highlights of a satellite symposium held at the XX world congress on Parkinson's disease and related disorders, Geneva, Switzerland, 8-11 December 2013 (2014) (2)
P2.159 Efflcacy and safety of once-daily (qd) pramipexole extended-release for advanced Parkinson's disease (2009) (2)
Transient restless legs syndrome after spinal anesthesia: A prospective study (2002) (2)
Movement Disorders in Neurologic and Systemic Disease: List of contributors (2014) (2)
Switching entacapone ‘non-responders’ to open-label opicapone: Change in absolute off-time following the 1-year extension BIPARK-I study (2019) (2)
Perimenstrual Fluctuations in Two Siblings With Early‐Onset Parkinson's Disease (2014) (2)
Atypical parkinsonian disorders (2005) (2)
Letter re: Incident parkinsonism in older adults without Parkinson disease (2017) (2)
Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study (2018) (2)
Global Long-Term Registry On Efficacy And Safety Of DUODOPA In Patients With Advanced Parkinson's Disease In Routine Care (GLORIA): 12-Month Interim Findings (S7.005) (2014) (2)
O0027 Rotigotine transdermal patch provides continuous efficacy in patients with moderate to severe idiopathic restless legs syndrome – 24 month results from a multi-national, multi-centre, open-label, follow-up trial (2007) (2)
Assessing treatment outcome in RLS trials and clinical care: CGI-I, PGI, or VAS? (2013) (2)
Criteria for Prodromal Parkinson ’ s Disease (2015) (2)
Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study (2021) (2)
Movement disorders in childhood metabolic diseases (2014) (2)
[Double bilateral carotid artery occlusion after blunt neck trauma (case report)]. (1981) (2)
15.14 Validation of the freezing of gait questionnaire (FOG-Q) in Parkinson's disease (2005) (2)
Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients (S26.003) (2018) (2)
Cleopatra-PD: Clinical efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease (2007) (2)
[Atypical Parkinson syndrome]. (1997) (2)
Efficacy of opicapone in patients with Parkinson's disease with levodopa dose reduction: a pooled post-hoc analysis of BIPARK-I and II (2020) (2)
Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach (2016) (2)
Parkinson disease Primer - a true team effort (2020) (2)
Biomarkers for Alzheimer's disease: a controversial topic (2015) (2)
Writer’s cramp, limb dystonia, and other task-specific dystonias (2007) (2)
PRODEST study: depressive symptoms in Parkinson's disease (2007) (2)
0739 GRAY MATTER ABNORMALITIES IN SLEEP WALKING (2017) (2)
Safety and tolerability of growth-hormone therapy in multiple system atrophy (2007) (2)
More on the restless legs syndrome and spinal anesthesia. (2009) (2)
Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects. (1991) (2)
A comparative study of rasagiline versus placebo or entacapone as adjunt to levodopa in Parkinson's disease (PD) patients with motor fluctuations (the LARGO Study). (2004) (2)
Neurodegenerative disease: Multiple system atrophy—new insight from prospective studies (2015) (2)
Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
Neurological research & training after the easing of lockdown in countries impacted by COVID-19 (2020) (2)
NS 2330, a DA reuptake inhibitor, in levodopa-treated patients with Parkinson's disease and motor fluctuations: The Phase II ADVANS study (2006) (2)
Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial (2022) (2)
Evoked potentials in a case of progressive multifocal leukoencephalopathy (2003) (2)
Global Long-term Registry on Efficacy and Safety of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care (GLORIA) - Interim Results in a Subgroup of Patients with Dyskinesia at Baseline (P1.192) (2015) (2)
Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants. (2022) (2)
Vertical supranuclear gaze palsy induced by deep brain stimulation: report of two cases. (2014) (2)
The natural history of Parkinson's disease. (1998) (2)
Neurological letter from Austria. (2009) (2)
The Natural History and Prognosis of Parkinson’s Disease (2002) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
What is new in movement disorders? (1999) (2)
Imaging markers of disease progression in multiple system atrophy (2019) (2)
Adoption (early levodopa with opicapone in Parkinson's patients with motor fluctuations) study in Parkinson's disease: Design and rationale of a randomized prospective, open-label exploratory trial (2021) (2)
Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trials (2019) (2)
Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II (2019) (1)
[The clinical definition of Parkinson's disease--time for a change?]. (2012) (1)
[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement]. (2008) (1)
Simple assessments of mobility. Methodology and clinical application of kinetic gait analysis. (2001) (1)
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline mao-b inhibitors use: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (1)
[Dementia with Lewy Bodies and its differentiation from Alzheimer's disease]. (2007) (1)
Corrigendum to "Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes" [Parkinsonism Relat. Disord. 21(3) (2015) 231-235]. (2016) (1)
Global Long-Term Registry on Efficacy and Safety of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care (GLORIA) - Interim Results on Non-Motor Symptoms (I3-3B) (2015) (1)
Advances in Research on Neurodegeneration (2000) (1)
Modafinil for the Treatment of Daytime Sleepiness in Parkinsons Disease: A Double-blind, Randomized, Crossover, Placebo-controlled Polygraphic Trial NEUROLOGIC DISORDERS (2002) (1)
DA agonists ‐ Non‐Ergot derivaties: Piribedil (2002) (1)
In ̄ uence of scene statistics on colour constancy (1)
The primary olfactory cortex in Parkinson's disease (PD) and incidental Lewy body disease (ILBD) (2007) (1)
Symptomatic hemiparkinsonism due to extensive middle and posterior fossa arachnoid cyst: case report (2020) (1)
Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s disease questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience (2019) (1)
085 RESTLESS LEGS SYNDROME IN FRIEDREICH ATAXIA: A POLYSOMNOGRAPHIC STUDY (2009) (1)
Severe dysphagia, myalgia, and rash in a 55‐year‐old man (2016) (1)
Therapeutic experiences with an abeorphine derivative in Parkinson's disease. (1987) (1)
Movement Disorders in Neurologic and Systemic Disease: Principles of management in movement disorders (2014) (1)
Abstracts of The Movement Disorder Society's Thirteenth International Congress of Parkinson's Disease and Movement Disorders. June 8-10, 2009. (2009) (1)
[Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa]. (1994) (1)
[Treatment of focal dystonia with botulinum toxin A]. (2001) (1)
Defining premotor Parkinson’s disease: a window of opportunity for neuroprotection? (2013) (1)
Sensory predominant neuropathy with GM1 antibodies, conduction blocks, and orbital pseudotumour (2000) (1)
DA agonists ‐ Ergot derivaties: Dihydroergocryptine (DHEC) (2002) (1)
Overview of Parkinsonism and Approach to Differential Diagnosis (2013) (1)
[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. (1995) (1)
Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter? (2021) (1)
DA agonists ‐ Non‐Ergot derivaties: Pramipexole (2002) (1)
Smelling Parkinson’s Disease: New Metabolomic Biomarker for PD (2019) (1)
Dopaminergic Imaging in Parkinson’s Disease: SPECT (2011) (1)
[Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs]. (1996) (1)
Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (1)
Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience (2019) (1)
Rivastigmine in Parkinson’s Disease Dementia (2006) (1)
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease (2022) (1)
Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited (2023) (1)
NEW DEVELOPMENTS FOR PARKINSON ’ S THERAPY WITH COMT INHIBITORS This symposium took place on 22 nd September 2016 as a part of the 89 th Deutsche Gesellschaft für Neurologie ( DGN ) Congress in Mannheim , Germany (2018) (1)
Disease Primers PARKINSON DISEASE (2017) (1)
P2.155 Simple overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage (2009) (1)
BouNDless: An active-controlled, randomised, double-blind, double-dummy trial of continuous subcutaneous infusion of levodopa/carbidopa with ND0612 in patients with Parkinson's disease (2020) (1)
Invasive Treatment Strategies in a Patient with PARK 15–Associated Parkinsonism (2015) (1)
Prodest - Depressive symptoms in Parkinson's disease: Demographic data (2007) (1)
Structural MRI in Idiopathic Parkinson Disease and Parkinsonism (2013) (1)
Advances in Research on Neurodegeneration (2000) (1)
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to gender: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (1)
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility? (2022) (1)
Supplement neuroimaging movement disorders (2009) (1)
Erratum: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study (2010) (1)
Lesions Associated with Visual Hallucinations and Psychoses (2010) (1)
[Myoglobin increase during tocolysis (author's transl)]. (1980) (1)
Different assessment tools to detect sarcopenia in patients with Parkinson's disease (2022) (1)
Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: A post-hoc analysis from combined BIPARK-I and II (2019) (1)
Baseline characteristics that influence “off” time improvement in levodopa-carbidopa intestinal gel-treated advanced Parkinson’s disease patients in the GLORIA registry (2017) (1)
Switching entacapone or placebo to opicapone Open-label: Efficacy results of the BIPARK-I 1-year extension study (2017) (1)
Writer’s cramp, limb dystonia and other task-specific dystonias (2007) (1)
Disturbance of time perception in left hemispheric migraine aura (1996) (1)
Restless Legs Syndrome and Parkinson's Disease (2010) (1)
Multimodal MRI reveals alterations of sensorimotor circuits in restless legs syndrome (2019) (1)
Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study (2022) (1)
Review: Friedreich Ataxia and Erythropoietin (2010) (1)
Sustained efficacy and tolerability of pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease (2010) (1)
Nighttime and morning OFF improvements with opicapone in patients with Parkinson's Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalyses (2020) (1)
161. Results from a double-blind and open-label phase 3 study of a novel liquid formulation of abobotulinumtoxinA (Dysport) in the treatment of cervical dystonia (2015) (1)
Tolcapone of its Use in the Management of (2005) (0)
Failure of neuroprotection by caspase inhibition in the double-lesion SND rat model (2005) (0)
Letters to the Editor (1998) (0)
Comparisons among responses to pramipexole extended-release as adjunctive treatment in Japanese and non-Japanese studies of advanced Parkinson's disease (2010) (0)
Investigation of Volatile Metabolites in Sebum as Prodromal Indicators of Parkinson’s Disease (2023) (0)
P2.153 Once-daily pramipexole extended-release (ER) demonstrated non-inferiority compared to immediate release (IR) tid dosing in early Parkinson's disease (2009) (0)
The medical treatment (2017) (0)
2.265 LONG-TERM SAFETY AND SUSTAINED EFFICACY OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASE (2012) (0)
11.5 Senile Chorea (2012) (0)
Non-motor Symptoms (NMS) Improvement is Positively Correlated with Baseline NMS Burden and Improved Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-carbidopa Intestinal Gel: A Post-hoc Analysis from the GLORIA Registry (P1.038) (2018) (0)
Health-related quality of life and pharmacotherapy in Parkinson's disease: results of a multi-country study of the EuroPA Study Group (2009) (0)
Movement disorders following non-metal intoxications (2014) (0)
Excessive daytime sleepiness in Parkinson’s disease (2009) (0)
Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. (2016) (0)
Rapid chelation of hepatic iron with deferasirox in aceruloplasminemia due to a novel gene mutation (2010) (0)
Response to: On the role of visual electrophysiology in parkinson's disease. (2017) (0)
Dopamine agonists in the treatment of Parkinson's Disease (1995) (0)
Gastrointestinal Safety of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinsonʼs Disease Patients: Interim Results From the GLORIA Long-Term Registry: 1462 (2015) (0)
Clinical Features of 13 Patients with Parkinson's Disease Due to an Autosomal Dominant Mutation in the Vacuolar Protein Sorting-Associated Protein 35 (VPS35) (P01.211) (2012) (0)
Nigral Degeneration in Animal Models of Multiple System Atrophy (2000) (0)
infarctionDiencephalic amnesia and apraxia after left thalamic (2000) (0)
Sustained off-time decrease in patients using pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease (2010) (0)
Faculty Opinions recommendation of Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. (2017) (0)
Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease (2022) (0)
An analysis of cognitive and behavioral features of MSA-P and MSA-C patients. (2010) (0)
I15 Sleep In Patients With Huntington’s Disease: Interim Results From A Polysomnographic Study (2014) (0)
P0052 Sleepiness and falling asleep in dopaminergic treated RLS: a polygraphic, double-blind, placebo-controlled, crossover study (2007) (0)
Patient Concept Elicitation Interviews: Insights into Multiple System Atrophy (MSA) Patient Experiences and Relevance of a modified United Multiple System Atrophy Rating Scale (P8-9.003) (2023) (0)
Influence of baseline off-time in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II (2019) (0)
Practice Issues Review : Neurological Rehabilitation in Austria: First Experience with a Newly Installed Structure (1998) (0)
Advances in Research on Neurodegeneration (1999) (0)
III.7 Treatment of depression in Parkinson's Disease (2006) (0)
Advances in Research on Neurodegeneration (1999) (0)
LibriAdvances in Research on Neurodegeneration, Volume 3 & 4, Springer Verlag, Boston/Dordrecht/London (1997) (1998) (0)
Austria (2009) (0)
Chapter 1 – General Introduction: Restless Legs Syndrome as a Neurological Conundrum (2009) (0)
1.297 Rotigotine transdermal patch is effective in the treatment of idiopathic RLS: Results of a 6 month, multicenter, double blind, placebo controlled trial in Europe (2007) (0)
Relationship between the MDS-UPDRS and Quality of Life : a large international multicenter study of 3206 patients (2018) (0)
Long-term safety and efficacy of transdermal rotigotine in advanced Parkinson's disease (2008) (0)
Preface (2008) (0)
Effects of minocycline in the MSA/SND double lesion rat model (2005) (0)
Disease Progression in Multiple System Atrophy—Novel Modeling Framework and Predictive Factors (2022) (0)
European populations Replication of restless legs syndrome loci in three (2009) (0)
[Life expectancy and disability in Parkinson disease]. (1994) (0)
A Long-term Study on Effectiveness of Levodopa-carbidopa Intestinal Gel Treatment in Advanced Parkinson’s Disease Patients (P5.066) (2018) (0)
DECISION MAKING IN IDIOPATHIC RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER (2011) (0)
Movement Disorders in Neurologic and Systemic Disease: Movement disorders in stroke (2014) (0)
DA agonists ‐ Overview (2002) (0)
Drugs to treat gastrointestinal motility problems (2002) (0)
Eldad Melamed 1942‐2015: Ave atque—A memorial (2016) (0)
ING INTEREST CONCERNING PATHOLOGIC DAYTIME SLEEPINESS IN PATIENTS WITH PARKINSON DISEASE (2005) (0)
International Meeting on Atypical Parkinsonian Disorders (2005) (0)
Movement Disorders in Neurologic and Systemic Disease: Movement disorders in encephalitis (2014) (0)
CHAPTER 72 – PARKINSON PLUS DISORDERS (2007) (0)
Chapter 17. Early (Uncomplicated) Parkinson's Disease (2008) (0)
α‐Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies using Cerebrospinal Fluid – a Systematic Review and Meta‐Analysis (2023) (0)
An Open Study of Evening Doses of Slow-Release L-Dopa (Madopar HBS) in Parkinson Patients with Nocturnal Disabilities (1990) (0)
Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II (2019) (0)
OFF/-ON-time changes after switching from entacapone or placebo to opicapone in patients ending the BIPARK-I extension study on opicapone 50-mg (2020) (0)
Dorsolateral nigral hyperintensity on 1. 5T vs. 3T susceptibility‐weighted magnetic resonance imaging in neurodegenerative parkinsonism (2023) (0)
V36 Health-related quality of life in patients with Parkinson’s disease in Europe: Multicenter study of the EuroPA Study Group (2011) (0)
2.249A Efficacy and safety of transdermal lisuride (LIS) in advanced Parkinson's disease (PD) (2007) (0)
2.263 PATIENT-REPORTED CONVENIENCE OF ONCE-DAILY VS TID DOSING DURING LONG-TERM STUDIES OF PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASE (2012) (0)
Myotonic myopathy with painful muscle contractions and decrease of symptoms by cold (1978) (0)
Optimising the effect of dopaminergic treatment in Parkinson ’ s disease Presented by : (2018) (0)
Changes in dynamic electromyographic-recordings following repetitive botulinum toxin treatment in dynamic equinus gait due to cerebral palsy (1999) (0)
Chapter 18. Late (Complicated) Parkinson's Disease (2008) (0)
The changing concept of Parkinson’s disease (2016) (0)
Contents Vol. 12, 2013 (2013) (0)
No. 128 Efficacy and Safety of AbobotulinumtoxinA in the Treatment of Cervical Dystonia: A Phase III Randomized Double-Blind Placebo-Controlled Study (2014) (0)
Monday, 10 December 200717.00–18.30Afternoon Industry Satellite SymposiumRoom B1.IS.4.3 Efficacy and safety of transdermal lisuride (LIS) in advanced Parkinson's disease (PD) (2007) (0)
Baseline Characteristics of Participants of the SPARK Trial, a Phase 2 Study of the anti-alpha-synuclein antibody Cinpanemab (BIIB054) in Parkinson’s Disease (1579) (2020) (0)
NEUROIMAGING (1996) (0)
Off- and on-time responder post-HOC analyses of pooled opicapone phase III studies (2017) (0)
Faculty Opinions recommendation of Colonic bacterial composition in Parkinson's disease. (2015) (0)
Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients (2021) (0)
Oleh Hornykiewicz (1926-2020). (2020) (0)
ASSESSMENT OF MOTOR SYMPTOMS IN A LONG-TERM SAFETY STUDY OF RIVASTIGMINE CAPSULES AND PATCH IN PATIENTS WITH DEMENTIA ASSOCIATED WITH PARKINSON'S DISEASE (2011) (0)
Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits (2016) (0)
Safinamide – a monoamine oxidase-B inhibitor and a glutamate modulator (2020) (0)
Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach (2023) (0)
Poster 156 Dysport®, AbobotulinumtoxinA, Improves Disease-Specific Quality of Life in Patients with Cervical Dystonia, as Measured by Patient-Reported Outcomes, in a Phase III, Randomized, Double-Blind, Placebo-Controlled Study (2014) (0)
Cervical dystonia in spinocerebellar ataxia (2007) (0)
Low Bone Mineral Density in Friedreich Ataxia (2014) (0)
The 8th International Conference on Alzheimer's and Parkinson's Diseases. Preface. (2008) (0)
Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations (2021) (0)
Movement Disorders in Neurologic and Systemic Disease: Preface (2014) (0)
Re: Patient‐based outcomes of cervical dystonia: A review of rating scales (2005) (0)
POSTER ABSTRACTS (2001) (0)
0010 Functional Brain Connectivity Alterations in Restless Legs Syndrome are Modulated by Dopaminergic Medication (2020) (0)
Gastrointestinal safety of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients: GLORIA long-term registry interim results (2016) (0)
Expert Consensus on the Use of On‐Demand Treatments for OFF Episodes in Parkinson's Disease: A Modified Delphi Panel (2023) (0)
0673 Multimodal MRI Reveals Alterations Of Sensorimotor Circuits In Restless Legs Syndrome (2019) (0)
0728 CHARACTERIZATION OF PATIENTS WITH LONG-TERM IDIOPATHIC REM SLEEP BEHAVIOR DISORDER (2017) (0)
Switching from double-blind entacapone or placebo to open-label opicapone: change in OFF-/ON-time from patients who ended the 1-year BIPARK-I extension on opicapone 50 mg (2019) (0)
Botulinum toxin (Dysportt) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study (2000) (0)
Netter's Neurology (2008) (0)
No. 127 Dysport® AbobotulinumtoxinA Improves Disease-Specific Quality of Life in Cervical Dystonia Patients as Measured by Patient-Reported Outcomes in a Phase III Randomized Double-Blind Placebo-Controlled Trial (2014) (0)
3-30-09 Interfernce of rhythmic constraints on gait in health subjects and patients with early Parkinson's disease (1997) (0)
Comprar Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis | Mark Hallett | 9780470085769 | Wiley (2009) (0)
L-DOPA THERAPY IN PARKINSON'S DISEASE: AN UPDATE AFTER 30 YEARS OF CLINICAL USE (2002) (0)
3.4 Differenzialdiagnosen (2012) (0)
A Case of Eight-and-a-Half-Syndrome as a Presenting Manifestation ofLate Onset Multiple Sclerosis (2016) (0)
First evidence for neurodegeneration in REM sleep without atonia (2015) (0)
Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data (2019) (0)
Botulinum toxininwriter's cramp: objective responseevaluation in31patients (2011) (0)
The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II (2022) (0)
480 PROLONGED SACRAL NEUROMODULATION TESTING WITH TINED LEADS: DOES IT INCREASE ADVERSE EVENTS? (2007) (0)
Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
Olfactory Dysfunction in Parkinson'S Disease (2013) (0)
Risk of dyskinesia in Parkinson's disease patients who already have developed wearing-off: A secondary analysis of STRIDE-PD study (2013) (0)
Patient-based outcomes of cervical dystonia : A review of rating scales. Author's reply (2005) (0)
Parkinson's disease severity levels and MDS-Uni ﬁ ed Parkinson's Disease Rating Scale Parkinsonism and Related Disorders (0)
Levodopa-carbidopa intestinal gel treatment in patients with <10 years of Parkinson's disease: GLORIA registry interim results (2016) (0)
Treatment of Motor Fluctuations in Parkinson’s Disease with Subcutaneous Apomorphine (1990) (0)
Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
P408 Does dystonic EMG-pattern influence the efficacy of botulinum toxin (BTX) in cervical dystonia (CD)? (1996) (0)
No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187) (2013) (0)
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Pet Study Using [ 11C ] PBR28 and Machine Learning Enhanced Analysis (2021) (0)
The Challenging Case of a Man With Paroxysmal Irregular Jerking of the Right Arm (2012) (0)
DA agonists ‐ Ergot derivaties: Bromocriptine (2002) (0)
PO19-WE-12 Treatment with recombinant human Erythropoietin: focus on iron status and possible mechanism for iron redistribution (2009) (0)
New delivery techniques in the drug treatment of Parkinson's disease (1992) (0)
A Patient With a Progressive Ataxia and Brain Iron Accumulation (2012) (0)
Klinische Differentialdiagnose der Parkinson-Syndrome (1993) (0)
Franz Gerstenbrand - Obituary. (2017) (0)
Faculty Opinions recommendation of Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. (2014) (0)
Availability of olfactory bulb and olfactory tract in brain specimens in a brain bank (2012) (0)
From OFF to ON—Treating OFF Episodes in Parkinson’s Disease (2020) (0)
Reply to “Nonmotor symptoms in subjects without evidence of dopaminergic deficit” authors: “Swallow DMA, Grosset KA, Grosset DG” (2016) (0)
Multiple System Atrophy: Clinical Features and Management (2010) (0)
Comment: Autologous mesenchymal stem cells (2019) (0)
Lack of selective vulnerability to anticholinergic induced cognitive impairment in early Parkinson's disease. (1991) (0)
[Magnetic resonance tomography in patients with Parkinson's disease and Parkinson-plus syndromes]. (1996) (0)
[Prognosis of traumatic coma]. (1979) (0)
Reply (2004) (0)
P102 A long-term study on the safety of rivastigmine capsule and patch in mild to moderate Parkinson’s disease dementia (2011) (0)
Parkinson-Biomarker aus der Haut (2021) (0)
Treatment of dementia in Parkinson's disease (2005) (0)
Natural Evolution and Life Expectancy in Parkinson’s Disease (2003) (0)
P20. Botulinum toxin treatment has no influence on auditory startle reaction in primary blepharospasm (2007) (0)
Abstracts of the 2021 European Federation of Autonomic Societies (EFAS) Congress (2022) (0)
Development of new treatments for Batten disease (2014) (0)
Non-Oral Drug Delivery Strategies: From Early Diagnosis to Advanced Treatments (2015) (0)
Using the anterior olfactory nucleus to study lewy pathology in olfactory structures (2013) (0)
diagnosis of spinal cord diseases . Magnetic resonance imaging in the and (0)
Faculty Opinions recommendation of A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. (2014) (0)
Foreword (1999) (0)
Movement disorders in systemic infections (2014) (0)
New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
Parkinson ' s syndrome . neurodegenerative disorders presenting with Absence of disease related prion protein in (0)
P07.20 Auditory startle reflex disinhibition in idiopathic restless legs syndrome (2006) (0)
“Histoblot”- A new tool for in-situ differentiation of amyloids and precursors in Alzheimer's disease and prion disorders (1992) (0)
Special Sessions (2010) (0)
Opicapone as first-line adjunctive levodopa treatment in Parkinson's disease patients with motor fluctuations: BIPARK-I and II combined post-hoc analysis (2020) (0)
VIDEO-PSG ANALYSIS OF MOVEMENTS DURING SLEEP IN 100 (2015) (0)
PO19-WE-01 Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin (2009) (0)
Dysport (abobotulinumtoxinA) botulinum toxin type A (2012) (0)
Multiple system atrophy. (2022) (0)
Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
Discussion: Session 8 — 9 A.M. - 8 February 1993 (1994) (0)
[Neurologic symptoms in 79 leprosy patients in Tanzania]. (1984) (0)
Abstracts of the 2022 European Federation of Autonomic Societies (EFAS) Congress (2022) (0)
The 17th meeting of the European Federation of Autonomic Societies (EFAS) (2017) (0)
[Botulinum toxin treatment -- state of the art 2000]. (2001) (0)
Reply: “Restless Legs Syndrome and Parkinson's Disease” (2010) (0)
Autologous mesenchymal stem cells: Hope for patients with multiple system atrophy? (2019) (0)
Add tags for "Advances in Research on Neurodegeneration". Be the first. Similar Items. Related Subjects: (5) Medicine. Toxicology. Neurology. Pathology. Psychiatry. Advances in Research on Neurodegeneration Volume 6. Editors: Poewe, Werner, Ransmayr, (2015) (0)
Expert Perspectives – Parkinson’s Disease Pathophysiology and Management (2018) (0)
Books Received (2001) (0)
Faculty Opinions recommendation of Subthalamic nucleus deep brain stimulation in isolated dystonia: A 3-year follow-up study. (2017) (0)
POEWE, Werner: Innsbruck/Austria (2019) (0)
Non-motor symptoms (nms) improvement is correlated with baseline nms burden and improved quality of life (QoL) in levodopa-carbidopa intestinal gel (LCIG) treated parkinson’s disease patients (2017) (0)
Poster 155 Dysport®, AbobotulinumtoxinA, is Effective with a Favorable Safety Profile in the Treatment of Cervical Dystonia: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study (2014) (0)
Diffusion-weighted MRI differentiates the parkinsonian variant of multiple system atrophy from Parkinsons disease (2001) (0)
[Value of palpation and auscultation in stenoses and occlusions of the carotid arteries]. (1985) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Werner H. Poewe?

Werner H. Poewe is affiliated with the following schools: